BHVN
Biohaven Ltd. · NYSE
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website biohaven.com
- Employees(FY) 202
- ISIN VGG1110E1079
Performance
-9.65%
1W
-14.62%
1M
-24.51%
3M
+25.99%
6M
-12.69%
YTD
+164.66%
1Y
Profile
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Investment Analysis Report: BHVN
Overview
In this investment analysis report, we will delve into the financial statements of Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue grow...
Technical Analysis of BHVN 2024-05-10
Overview:
In analyzing the technical indicators for BHVN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-16 06:26
Daily – Vickers Top Buyers & Sellers for 05/16/2024(Argus Research)
- 2024-05-15 11:00
- 2024-05-14 09:35
- 2024-05-13 09:35
- 2024-05-09 16:05
- 2024-05-09 11:54
BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024(Investorplace)
- 2024-05-09 04:05
- 2024-05-01 02:38
- 2024-04-26 07:05
Independent Director of Biohaven John Childs Buys 3.2% More Shares(Simply Wall St.)
- 2024-04-26 07:00
Daily – Vickers Top Buyers & Sellers for 04/26/2024(Argus Research)
- 2024-04-26 06:00
3 Biotech Stocks to Buy on the Dip: April 2024(InvestorPlace)
- 2024-04-25 18:00
3 Biotech Stocks to Buy on the Dip: April 2024(Investorplace)
- 2024-04-25 11:00
- 2024-04-23 11:00
- 2024-04-22 16:05
- 2024-04-22 04:05
- 2024-04-18 06:00
- 2024-04-17 18:00
- 2024-04-17 16:05
- 2024-04-17 04:05
- 2024-04-13 09:00
- 2024-04-12 21:00
- 2024-04-03 22:03
- 2024-03-20 07:59
Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock(Simply Wall St.)
- 2024-02-29 16:05
- 2024-02-29 03:05
- 2024-02-18 07:10
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)(Simply Wall St.)
- 2024-01-25 17:31
- 2024-01-22 07:00
Obesity Drugs Lead to Muscle Loss—Pharma Companies Want to Fix That(The Wall Street Journal)
- 2024-01-08 07:30
Page 1 of 5
previousnext